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Objectives: Previously in Finland, each municipality selected which methods to use in
screening for fetal abnormalities. This resulted in practice variation and inequity. The
national health technology assessment (HTA) office Finohta compared the methods and
time frames available when screening for chromosomal and structural abnormalities. The
assessment identified a need to discuss several value-laden questions before policy
decisions could be taken.
Methods: The National Screening Committee (NSC) at the Ministry of Health and Social
Affairs (MOH) formulated a statement based on the HTA report to inform policy makers.
This article describes the steps in the policy process.
Results: The national screening committee organized an open forum to discuss the
ethically relevant aspects of fetal screening, and a lengthy public discussion highlighted
the viewpoints of various stakeholders. Based on the assessment, public discussion, and
several committee meetings that heard further experts, the NSC formulated a conclusion
based on equity of access. This also offered options for families unwilling to terminate a
pregnancy due to fetal abnormality. The MOH sent the conclusion to a comment round,
and the proposal was accepted with minor adjustments. The Ministry decided to unify the
regulation of all public screening programs by one statute. The policy process lasted three
years, and the methods to screen for fetal abnormalities will be unified after a further 3
years.
Conclusions: The assessment of screening programs for fetal abnormalities reached
beyond its original mandate. The process of examining values behind screening resulted
in a program that respects the differing objectives and ethical values of pregnant families,
and to national legislation on screening programs.
Keywords: Screening, Health policy, Prenatal, Pregnancy, Fetus, Chromosomal
abnormalities, Malformation
Major congenital abnormalities are detected in 2 to 3 births
per 100, and 1 per 100 is affected by several major anomalies
We thank the members of the HTA project on prenatal screening. We also
thank the members of the national Screening Committee for their commit-
ment to reach a statement that would ensure equity of care for all pregnant
women.
or a syndrome (5;6; Finnish Registry of Congenital Malfor-
mations). The most severe anomalies can lead to perinatal
death or permanent disability. Some disorders can be treated
during the fetal period or require immediate treatment after
birth to reduce permanent disability or prevent the death of
the newborn.
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The methods to screen for chromosomal abnormalities,
especially trisomy 21 (Down syndrome) have been in use
since the 1980s (7) and are still developing (12). Ultrasound
techniques are increasingly used to screen for structural ab-
normalities of the fetus. The chances of detecting structural
abnormalities vary depending on the type and severity of
the anomaly, the scanning equipment, the experience of the
sonographer and the timing of screening (5;9;10). The ex-
isting variations and difficulties in determining when a mal-
formation is severe, moderate, or mild raises major ethical
questions every time a malformation is identified during the
fetal period.
Between and within countries there is considerable vari-
ation in the use of various existing screening methods. In
Finland, each of the over 400 municipalities can indepen-
dently decide which screening method to provide, resulting
in a wide variety in practices, inequity, and major problems
in counseling and organizing the investigations. According
to a survey in 2002, forty of the forty-four hospitals with a
maternity clinic offered a nuchal translucency measurement
for chromosomal screening but only four of them combined it
with serum markers (11). Forty hospitals offered age-based
direct invasive diagnostic procedures (chorionic villi sam-
ple or amniocentesis) to detect chromosomal anomalies. Of
these, four had set the age limit at 35, one at 36, seven-
teen at 37, three at 38, three at 39, and twelve at 40 years.
In Finland, ultrasound examination has only been offered
as part of screening (measurement of nuchal translucency
or screening for structural malformations) or due to clinical
symptoms.
The Finnish organization for gynecologists and the local
health decision makers requested a health technology assess-
ment (HTA) on the topic, while the Ministry of Health and
Social Affairs also needed this information to be used as a
basis for policy decisions. In this article, we describe the pro-
cess from initial request to a national statute on screening.
The questions identified by the HTA assessment, the process
of answering these questions and the selection of screening
methods to be offered for pregnant women in Finland are
presented.
ASSESSMENT OF OPTIONS FOR
SCREENING FOR STRUCTURAL AND
CHROMOSOMAL ABNORMALITIES
The HTA assessment was conducted together with method-
ological experts on HTA (IAR, MM) and health economics,
the head of the national registry for anomalies, and a panel
of clinical experts in obstetrics, neonatology, general prac-
tice, and clinical genetics. In addition to being methodolog-
ical experts, the authors of this article are also clinical ex-
perts in pediatric neurology (I.A.R.) and general practice
(M.M.).
The possible screening models for Finland were con-
structed using evidence from the literature and the clinical
experts (1). Optimal methods and time frames to be used
when screening for chromosomal abnormalities were iden-
tified in a recent HTA report (12). For the chromosomal
abnormalities, the following options were considered to be
applicable in Finland. (i) The combination of serum markers
(PAPP-A andβ-HCG at gestation week 8 to 10) and measure-
ment of nuchal translucency (ultrasound at gestation week 10
to 12), (ii) triple serum markers (estriol, β-HCG, AFP at ges-
tation week 14 to 15), or (iii) a combination of i and ii. For
structural abnormalities, the options were based on recent lit-
erature on the detection rate during different gestation weeks
(5;8–10), on Finnish legislation on the termination of preg-
nancy, and on equity in care. The options were (i) ultrasound
screening during gestation week 18 to 21 and (ii) ultrasound
screening after gestation week 24 for parents to whom ter-
mination of pregnancy would not be an option. In Finland,
induced abortion due to fetal abnormalities is legal until the
end of the 24th gestation week.
The costs of the various screening methods were calcu-
lated in euros at the 2004 price level. The effects and costs
of various screening options were compared against a no-
screening situation with the assumption that 90 percent of
the pregnant women would participate. Sensitivity analyses
were done for screening costs based on different participation
rates. An example of the comparison of both chromosomal
and structural screening against no screening situation is pre-
sented in Table 1.
The expert group also identified the ethical consequences
of each screening model. The HTA draft was sent to external
experts for peer review before publishing and their comments
were included in the ethical evaluation. A summary of the
ethical evaluation has been previously published (2).
Although the expert group could identify the best pos-
sible screening methods, several critical questions needed
answering before a national decision could be taken on a
uniform screening system. Questions regarding the aims of
the screening programs are presented in Table 2. The expert
group further required that the decision has to provide equity
within the country. In addition, the quality of the screening
program needs to be ensured (e.g., improved counseling at
all levels of the screening program, criteria for training the
sonographs, the need for centralization, requirements for the
ultrasound equipment, setting the sensitivity and specificity
levels, follow-up of induced harm).
THE DECISION PROCESS IN THE
NATIONAL SCREENING COMMITTEE
The Screening committee at the Finnish Ministry of Social
Welfare and Health was ready in October 2003 to evaluate the
existing and proposed screening programs in Finland. Both
authors of this article are members of the Screening Com-
mittee and had, thus, the opportunity to inform the Screening
Committee during the HTA project, present the report, and
answer content-specific questions. The Screening Committee
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recognized that the goal of the prenatal screening programs
is to allow parents to take informed decision about the preg-
nancy. These decisions range from termination of pregnancy
to optimal care during pregnancy and delivery. It was con-
sidered important to discuss the list of questions (examples
in Table 2) in the HTA report with all stakeholders and an
open seminar was organized.
Four hundred persons, from laypersons to health deci-
sion makers, participated in the seminar in October 2005.
The seminar started with a computerized survey of the par-
ticipant’s opinions. The participants answered each question
through remote control, and the results were shown immedi-
ately. The seminar included lectures and a panel discussion
also involving patient organizations and layperson. The sur-
vey questions were repeated at the end of the seminar. The
information received during the seminar had a clear impact
on the opinions of the participants (Table 3). The seminar
revealed new issues for the Screening Committee to tackle
before issuing a final statement.
The Screening Committee invited the principal investi-
gator at the national registry for fetal abnormalities to discuss
the various scenarios following the options of each screening
program. Finally, after six meetings and close to 1 year of
hard work, the Screening Committee unanimously recom-
mended a national screening program (the content explained
later) that would ensure equity in care by providing the best
currently available screening options for the citizens. Fur-
thermore, the Screening Committee recommended that the
effects and quality of the screening programs must be con-
tinuously monitored and quality ensured by a national group
of experts. This group will determine the requirements for
equipment and personnel in the program. The personnel in
primary care (maternal health clinics) and secondary and ter-
tiary hospitals needs training to give adequate and objective
information and counseling.
THE PROCESS AT THE MINISTRY OF
HEALTH AND SOCIAL AFFAIRS
The Ministry of Health and Social Affairs accepted the state-
ment of the Screening committee and sent it for a wide round
of commenting, including health decision makers, content
experts, ethicists, and patient organizations. A total of forty-
seven comments were given. The statement was well re-
ceived, with only minor clarifications required. The ministry
had further asked whether the uniform screening program
should be implemented through a recommendation, a code
of practice or a statute. Twenty of the respondents favored
compulsory implementation by means of a statute so as to
reach equity in care, whereas seven favored a recommenda-
tion and the rest were undecided.
After weighing the different options, the Ministry de-
cided to regulate the screening programs for fetal abnormali-
ties through a statute. As this strategy would increase the cost
burden for communities, the ministry requested an estimate
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Table 2. Critical Questions on the Aim of Prenatal Screening
Screening for chromosomal abnormalities
Is it justified to screen for an abnormality that cannot be treated and leads to miscarriage or perinatal death (e.g., trisomies 13 and 18)?
Is it justified to screen for an abnormality that cannot be treated and leads often to miscarriage but can also lead to perinatal death, birth
of a child with several other malformations, or birth of a child with only mild mental retardation (e.g., trisomy 21)?
If it is considered justified to screen for these abnormalities, how large should the risk of chromosomal abnormality be so that screening
and invasive investigations are justified against the risk of miscarriage due to invasive diagnostic procedures?
If screening is offered only to older pregnant women, what would be the age limit?
If screening for chromosomal abnormalities is not publicly funded, what actions need to be taken in regards to offering screening in
private clinics?
Screening for structural malformations
Is it justified to screen for an abnormality that cannot be treated and leads to miscarriage or perinatal death (e.g., anencephaly)?
Is it justified to screen for an abnormality that cannot be treated and can lead to a handicap of wide severity, ranging from total
independence to continuous need for help (e.g., spina bifida)?
Is it justified to screen for an abnormality for which the outcome can be improved if care in pregnancy, in delivery, and for the newborn
can be planned optimally (e.g., heart malformations)?
If the aim is on the one hand to allow termination of pregnancy in case of identified fetal abnormality but also to provide optimal care in
pregnancy, in delivery, and for the newborn, when should the ultrasound be offered?
If the aim is to identify only abnormalities for which a treatment that improves the prognosis exists, when is the optimal timing for
ultrasound scan?
If screening for structural abnormalities is not publicly funded, what actions need to be taken with regard to offering screening in private
clinics?
Table 3. Survey of Opinions on Various Ethically Relevant Issues within the Context of Various Screening Options
At the beginning
of the seminar
At the end of the
seminar
Questiona Yes (%) No (%) Yes (%) No (%)
Is it justified to screen for an abnormality that cannot be treated and leads to miscarriage or
perinatal death (e.g., trisomies 13 and 18)?
65 31 76 21
Is it justified to screen for an abnormality that cannot be treated and leads often to miscarriage or
perinatal death, but the person can also have fairly good quality of life up to adulthood (e.g.,
trisomy 21)?
75 20 68 31
Is it justified to screen for a structural abnormality that cannot be treated and the severity of the
handicap can vary from severe to mild (e.g., spina bifida)?
83 14 86 13
Is it justified to screen for a structural abnormality that can be treated and thus the prognosis can
be improved (e.g., heart malformation)?
92 6 94 5
Invasive diagnostic procedure in chromosomal screening can lead to miscarriage in about 1/100.
What is the acceptable percentage of participants that are offered invasive diagnostic
procedures?
1% 14 11
3% 19 39
5% 20 29
10% 8 3
Should the family themselves be allowed to choose the method to screen for chromosomal
abnormalities?
67 26 54 37
Should the family be allowed to choose the timing for structural ultrasound scan? 43 50 59 38
Should the structural ultrasound screening be performed
In University hospitals only 9 10
In University and Central hospitals only 43 65
In all maternity clinics 25 18
Only in one center in Finland 10 2
Should Finland offer screening for chromosomal and structural abnormalities with
A nationally uniform screening program 75 98
A uniform screening program within a University hospital district 12 2
A uniform screening program within a hospital district 7 0
A program according to the wishes of each municipality 3 0
Note. Only “yes” and “no” answers are presented in the table, percentage of “don’t know” answers can be counted when adding up to 100%.
aAnswers are given in parentheses.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 23:4, 2007 439
A
utti-R
a¨
m
o¨
a
nd
M
a¨kela¨
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chromosomal screening or 
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Figure 1. The various pathways when deciding on participation.
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on the cost-impact of the various screening options on the mu-
nicipalities. This estimate was not possible within the given
time frames, as the Finohta report on fetal abnormalities had
not looked at the costs of all program options recommended
by the Screening Committee. Furthermore, the change in
cost-impact would have to be calculated for each munic-
ipality separately, as they were offering various screening
methods and the participation rates varied markedly between
the municipalities. Only crude estimates could be given but
they were regarded as sufficient to proceed with the statute.
The Ministry of Health and Social Affairs decided to
give a new umbrella statute on all screening programs. The
official screening programs—mammography screening for
women 50 to 69 years of age, screening for cervical can-
cer, and prenatal screening for structural and chromosomal
abnormalities—are now included in one statute, approved
by the Council of State on 21 December 21 2006. The uni-
form screening for structural and chromosomal abnormalities
must be adopted in all municipalities by the end of 2010 at
the latest.
The explanatory memorandum of the statute sets the
criteria for the evaluation of all screening programs that have
to be fulfilled before any program can be offered by public
health care. These criteria were originally formed by the
national Screening Committee (3). Furthermore, the quality
and possible harms of any screening program have to be
continuously monitored.
THE CONTENT OF THE NATIONAL
PRENATAL SCREENING PROGRAM FOR
STRUCTURAL AND CHROMOSOMAL
ABNORMALITIES
The content of the statute for the prenatal screening program
is explained in depth in the explanatory memorandum. The
main content of the statute is as follows: (i) General ultra-
sound during gestation week 10–14 to provide information
on length of gestation, plurality, site of fetus. (ii) Screening
for chromosomal abnormalities primarily by a combination
test: serum markers PAPP-A and β-HCG at 8–11 gestation
weeks and nuchal translucency measurement in gestation
weeks 10 to 12 in connection with a general ultrasound scan.
Alternatively, the triple test (serum markers AFP, β-HCG,
estriol) on gestation weeks 14 to 15. Women 40 years of
age or older can be offered direct fetal chromosomal analy-
sis (placental biopsy or amniocentesis) as an option. Nuchal
translucency measurements have to be centralized so that the
sonographer performs at least 200 measurements per year.
(iii) Screening for structural abnormalities is offered during
gestation weeks 18 to 21 if the parents consider termination
of pregnancy due to identified severe fetal malformation as
an option for their family. If the parents would not consider
termination of pregnancy as their informed choice under any
circumstances, the scan can be made first after the 24th ges-
tation week. The ultrasound screening for structural abnor-
malities have to be centralized so that the unit performs at
least 2000 screening scans per year and has the possibility
to consult an obstetrician specialized in ultrasound investiga-
tions. The time frames and various options are summarized
in Figure 1.
DISCUSSION
Variation in prenatal screening practices in Finnish munici-
palities had resulted in inequity in care. To solve this prob-
lem, an HTA project was launched to help decision makers in
choosing best possible screening programs. The assessment
was accomplished, but it identified major policy questions
that needed public discussion before deciding on how to pro-
ceed. The new national Screening Committee opened up the
discussion, actively involving health decision makers, pro-
fessionals, representatives of patient organizations, and the
general public
The National Screening Committee compared the differ-
ent screening options against no publicly funded screening
for fetal abnormalities. The need to ensure equity in care was
a clear priority. The statement by the Screening committee re-
quired much background work, interchange of opinions and
weighing the consequences of various value-laden options.
We participated both in the HTA project and were members
of the Screening Committee so we could provide detailed
information at the point when the Committee weighed the
different scenarios and screening options. This close cooper-
ation was essential for the content of the final statement.
The National Screening Committee also discussed what
could be regarded as an acceptable false positive rate in chro-
mosomal screening as the invasive diagnostic procedures can
lead to miscarriage. The rate of miscarriage is around 1 per-
cent (12), being slightly higher after chorionic villi sample
than after amniocentesis, and in addition to which the rate
of complications is dependent on the performer’s experi-
ence (4). The national screening committee suggested that
the specificity of the method should be set at 97 percent for
the combination test and 95 percent for the triple test. The
final levels for sensitivity and specificity must be defined by
a national group of experts that will start their work autumn
2007.
Neither Finohta, the National Screening Committee, nor
the Ministry had originally planned for a new statute on
screening. The wide acceptance of the statement on prena-
tal screening, the strong request to regulate this screening
program by means of a statute, and the need to respect the
rights of all pregnant women eventually led to the decision
that a statute is the only possibility to ensure a uniform and
justified screening program.
CONCLUSION
The HTA project on evaluating the various screening program
for fetal chromosomal and structural abnormalities reached
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beyond its original task. Questioning the values of these
screening programs led to a nationally uniform screening
program in which the objectives and ethical values of vari-
ous families have been taken into account. In addition, the
process supported the formation of an umbrella statute on
screening.
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